Data gathered: December 22
AI Stock Analysis - Immunitybio (IBRX)
Analysis generated October 30, 2024. Powered by Chat GPT.
ImmunityBio is a clinical-stage immunotherapy company dedicated to developing next-generation cancer treatments. Focused on boosting the immune system to fight cancer, their comprehensive platform includes a number of novel immunotherapy treatments currently in various stages of development. The company leverages cutting-edge technology and research to drive forward the efficacy and safety of its innovative therapies.
Stock Alerts - Immunitybio (IBRX)
 |
Immunitybio | December 18 Price is down by -5.1% in the last 24h. |
|
Immunitybio | December 17 Price is down by -5.2% in the last 24h. |
|
Immunitybio | December 16 Price is up by 5.9% in the last 24h. |
|
Immunitybio | December 13 Price is down by -5.6% in the last 24h. |
Alternative Data for Immunitybio
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 31 | Sign up | Sign up | Sign up |
| Sentiment | 84 | Sign up | Sign up | Sign up |
| Webpage traffic | 13,000 | Sign up | Sign up | Sign up |
| Employee Rating | 56 | Sign up | Sign up | Sign up |
| Google Trends | 15 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 43 | Sign up | Sign up | Sign up |
| Facebook Followers | 2,571 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 23 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 17,830 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,953 | Sign up | Sign up | Sign up |
| Twitter Mentions | 23 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 36 | Sign up | Sign up | Sign up |
| Linkedin Employees | 588 | Sign up | Sign up | Sign up |
About Immunitybio
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases.
| Price | $2.62 |
| Target Price | Sign up |
| Volume | 7,840,000 |
| Market Cap | $1.91B |
| Year Range | $2.62 - $9.15 |
| Dividend Yield | 0% |
| Analyst Rating | 50% buy |
| Industry | Biotechnology |
In the news
 |
ImmunityBio, Inc. (NASDAQ:IBRX) Shares Acquired by State Street CorpDecember 22 - ETF Daily News |
|
XTX Topco Ltd Has $346,000 Stake in ImmunityBio, Inc. (NASDAQ:IBRX)December 17 - ETF Daily News |
|
Captrust Financial Advisors Buys Shares of 11,073 ImmunityBio, Inc. (NASDAQ:IBRX)December 17 - ETF Daily News |
|
ImmunityBio (NASDAQ:IBRX) Reaches New 52-Week Low – What’s Next?December 14 - ETF Daily News |
|
ImmunityBio Announces Public Offering and Debt RestructuringOn December 10, 2024, ImmunityBio, Inc. (NASDAQ: IBRX) reported key financial updates through an 8-K filing with the Securities and Exchange Commission (SEC). The company entered into an undDecember 12 - ETF Daily News |
D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public OfferingDecember 12 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 6.1M | 36M | -30M | -86M | -56M | 0.000 |
| Q2 '24 | 1M | 50M | -78M | -135M | -104M | -0.200 |
| Q1 '24 | 40,000 | 42M | -42M | -134M | -104M | -0.200 |
| Q4 '23 | 140,000 | 34M | -34M | -233M | -201M | -0.350 |
| Q3 '23 | 82,000 | 32M | -32M | -96M | -60M | -0.190 |
Insider Transactions View All
| BLASZYK MICHAEL D filed to buy 71,915 shares at $2.8. June 5 '23 |
| BLASZYK MICHAEL D filed to buy 23,430 shares at $2.7. June 5 '23 |
| BLASZYK MICHAEL D filed to buy 71,430 shares at $2.8. June 5 '23 |
| Brennan John Owen filed to buy 5,000 shares at $2.7. June 5 '23 |
Similar companies
Read more about Immunitybio (IBRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Immunitybio?
The Market Cap of Immunitybio is $1.91B.
What is the current stock price of Immunitybio?
Currently, the price of one share of Immunitybio stock is $2.62.
How can I analyze the IBRX stock price chart for investment decisions?
The IBRX stock price chart above provides a comprehensive visual representation of Immunitybio's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Immunitybio shares. Our platform offers an up-to-date IBRX stock price chart, along with technical data analysis and alternative data insights.
Does IBRX offer dividends to its shareholders?
As of our latest update, Immunitybio (IBRX) does not offer dividends to its shareholders. Investors interested in Immunitybio should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Immunitybio?
Some of the similar stocks of Immunitybio are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.